ClinicalTrials.gg
Active, not recruitingNCT05557838TREMENDOUSUpdated Jun 26, 2026

Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC

A Phase 3 interventional study of Durvalumab and Tremelimumab in Hepatocellular Carcinoma, sponsored by AstraZeneca. Active, not recruiting at 29 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
214
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing durvalumab in Carcinoma, Hepatocellular — 22 open to participants now, 32 under way, 4 of them phase 3. durvalumab · Carcinoma, Hepatocellular.

Enrollment
5th of 42
214 · median 37
Started
2023
with 8 others
Phase 3
5 of 42
1 open now
Primary completion
2026-09
later than 13 of 31 live
Registered
21st of 42
by date
Lead sponsor
7 of 42
AstraZeneca

Among the 42 studies testing durvalumab in Carcinoma, Hepatocellular, this one is the 5th largest by enrollment, is one of 9 that started in 2023, is one of 5 in phase 3, reaches primary completion later than 13 of the 31 other live ones, and was the 21st registered.

Carcinoma, Hepatocellular

3,652 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,065 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

22 of the 42 studies testing durvalumab in Carcinoma, Hepatocellular are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 741 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 251 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing durvalumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This is a prospective, open label, multi-center, interventional study to assess the safety and efficacy of Druvalumab plus Tremelimumab as first-line treatment in Chinese patients with unresectable hepatocellular carcinoma.

Read the detailed description

Based on the promising result of HIMALAYA and study 22, this study is going to evaluate the efficacy and safety of Durvalumab plus Tremelimumab in Chinese population and some extended population compared to HIMALAYA, such as Child-Pugh B and, ECOG PS2.

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For inclusion in the study, patients should fulfill the following criteria:

  1. Provide written to participate in the study before the start of the study
  2. Age ≥18 years at the time of study entry.
  3. Body weight >30 kg.
  4. Confirmed HCC based on histopathological findings from tumor tissue or radiologically findings.
  5. Must not have received prior systemic therapy for HCC.
  6. At least 1 , not previously irradiated, that can be accurately measured at baseline as ≥10 mm in the longest diameter (except lymph nodes, which must have a short axis ≥15 mm) with computerized tomography (CT) or magnetic resonance imaging (MRI), and that is suitable for accurate repeated measurements as per 1.1 guidelines. A lesion which progressed after previous ablation or TACE could be measurable if it meets these criteria.
  7. Must not be eligible for locoregional therapy for unresectable HCC. For patients who progressed after locoregional therapy for HCC, locoregional therapy must have been completed ≥28 days prior to the baseline scan for the current study.
  8. Barcelona Clinic Liver Cancer (BCLC) stage B (that is not eligible for locoregional therapy) or stage C.
  9. Score classification on liver disease and PS at enrolment must comply with one of the following criteria, not cumulatively:

    1. Child-Pugh Score class A with WHO/ECOG PS 0-1 at enrolment will be enrolled in cohort1;
    2. Child-Pugh class B with WHO/ECOG 0-1 will be enrolled in cohort 2;
    3. Child-Pugh class A with WHO/ECOG 2 will be enrolled in cohort 2;

Exclusion criteria

Exclusion Criteria

1) Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).

2)Previous study drug(s) assignment in the present study. 3)Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.

4)Have received an product within 28 days prior to the first dose of study drug(s).

5) Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event () Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria:

  • Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis.
  • Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab or tremelimumab may be included (eg, hearing loss).

    6) Any concurrent chemotherapy, or biologic or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (eg, hormone replacement therapy) is acceptable.

    7) Known allergy or to any of the study drugs or any of the study drug .

    8) Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 28 days of the first dose of study drug(s).

    9) Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of study drug(s). Note: Local surgery of isolated lesions for palliative intent is acceptable.

    10) History of allogeneic organ transplantation (eg, liver transplant). 11)History of hepatic encephalopathy within past 12 months or requirement for medications to prevent or control encephalopathy (eg, no lactulose, rifaximin, etc. if used for purposes of hepatic encephalopathy).

    12) ascites, defined as ascites requiring increasingly frequent non-pharmacologic intervention (eg, paracentesis) and/or escalation in pharmacologic intervention to maintain symptomatic control, within 2 months prior to the first scheduled dose. Subjects on stable doses of diuretics for ascites for ≥2 months are eligible. Also, uncontrolled pleural effusion, pericardial effusion requiring recurrent drainage procedures (once monthly or more frequently) .

    13)Patients with main portal vein tumor thrombosis (Vp4). 14)Active or prior documented GI bleeding (eg, esophageal varices or ulcer bleeding) within 6 months.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
214 participants (actual)

Study arms

  • Experimental
    cohort 1

    durvalumab in combination with tremelimumab

    Drug: Durvalumab · Drug: Tremelimumab

  • Experimental
    cohort 2

    durvalumab in combination with tremelimumab

    Drug: Durvalumab · Drug: Tremelimumab

Interventions

  • Durvalumab IV (intravenous infusion)

    Also known as: MEDI4736

  • Tremelimumab IV (intravenous infusion) CTLA-4 inhibitor

    Also known as: There is no other names for tremelimumab.

06

What researchers measure

Primary outcomes

  1. ≥Grade 3 Adverse Events and Adverse Events of Special Interest of Cohort 1

    Safety endpoint

    Time frame: From the time of signature of informed consent, throughout the treatment period, and up to the follow-up period, assessed up to 44months

Secondary outcomes

  1. ≥Grade 3 Adverse Events and Adverse Events of Special Interest of Cohort 2

    Safety endpoint

    Time frame: From the time of signature of informed consent, throughout the treatment period, and up to the follow-up period, assessed up to 44 months

  2. Overall Survival (OS)

    efficacy endpoint

    Time frame: From the first dose of treatment to the date of death, regardless of the actual cause of the subject's death, assessed up to 44 months

  3. Progression Free Survival (PFS) per RECIST v1.1/mRECIST

    efficacy endpoint

    Time frame: From first dose of treatment until progression per RECIST 1.1/ mRECIST as assessed by the Investigator or death due to any cause prior to progression, assessed up to 15 months

  4. Objective Response Rate (ORR) per RECIST 1.1/ mRECIST

    efficacy endpoint

    Time frame: Until progression, assessed up to 15 months

  5. Disease Control Rate (DCR) per RECIST 1.1/ mRECIST

    efficacy endpoint

    Time frame: Until progression, assessed up to 15 months

  6. Duration of response (DoR) per RECIST 1.1/mRECIST

    efficacy endpoint

    Time frame: From the first dose, until progression, assessed up to 15 months

07

Study locations

29 sites
  • Research Site
    Beijing, 100021, China
  • Research Site
    Beijing, 100142, China
  • Research Site
    Beijing, 211405, China
  • Research Site
    Beijing, CN-100730, China
  • Research Site
    Changsha, 410005, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Fuzhou, 350011, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Guangzhou, 510100, China
  • Research Site
    Guangzhou, 510260, China
  • Research Site
    Guangzhou, 510515, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Harbin, 150081, China
  • Research Site
    Jinan, 2501117, China
  • Research Site
    Nanjing, 2100008, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Ningbo, 315010, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 200040, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Tianjin, 300000, China
  • Research Site
    Wenzhou, 325000, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuhan, 430079, China
  • Research Site
    Xi'an, 710038, China
  • Research Site
    Zhangjiagang, 215699, China
  • Research Site
    Zhengzhou, 450008, China
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient- level data from AstraZeneca group of companies sponsored clinical trials via the request portal. Plan Description: All request will be evaluated as per the Az disclosure commitment: https://astrazenecaarouptrials.pharmacm.com/ST/Submission/Disclosure Yes. indicates that Az are accepting requests for IPD ,but this does not mean are quests will be shared

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitment at made to the EFPIA Pharma Data Sharing Principles .For details of our timeline please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement(non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to a air access. For additional details. please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Sep 2026, 43 months after the start.

Of 53 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's planned 43 months is below that.

Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2022
First posted
Sep 28, 2022
StartActual
Feb 15, 2023
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05557838
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 28, 2022
Start date
Feb 15, 2023
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Jun 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Tremelimumab

Start the discussion